What a Denial Letter Actually Tells You
If a pharmacy told you your plan will not cover Wegovy or Zepbound, the reason usually falls into one of three categories, and knowing which one you got determines what you can do next.
The first is a formulary exclusion, meaning the drug is not on your plan's covered list at all. The second is a prior authorization denial, meaning the drug is covered in principle but your submitted documentation did not meet the plan's criteria. The third is a step therapy requirement, meaning the plan wants you to try something else first.
These are different problems with different remedies. A prior authorization denial is often fixable with better documentation. A formulary exclusion generally requires a formulary exception request, which is a separate process. Your denial notice is required to state the reason and the appeal deadline, and that document is the starting point for everything that follows.
The scale of the problem is not individual. According to GoodRx tracking published this month, the share of commercially insured people with no coverage for Zepbound rose from 51 percent in 2025 to 60 percent as of July 2026, leaving more than 114 million people without coverage. Restricted coverage for Zepbound fell from 45 percent to 37 percent. For Wegovy, unrestricted coverage slipped from 10 percent to 9 percent while restricted coverage rose slightly to 77 percent, with 27 million people still lacking coverage.
What the Value Analysis Says About Price
Here is the part that frustrates patients most: the independent value assessment concluded these drugs are worth what they cost, and plans are still declining to pay.
The Institute for Clinical and Economic Review published its final evidence report on obesity treatments in December 2025. Using estimated net prices, ICER calculated cost-effectiveness ratios of $66,355 per quality-adjusted life year for injectable semaglutide, $75,456 for oral semaglutide, and $57,779 for tirzepatide, compared with lifestyle modification alone. All three fall within commonly used value thresholds.
"Semaglutide and tirzepatide have revolutionized the management of obesity," said ICER Chief Medical Officer David Rind, MD, MSc, noting that beyond weight loss, the therapies reduce cardiovascular risk and improve other aspects of metabolic syndrome.
The problem is budget impact, which is a different calculation. ICER estimated that fewer than 1 percent of eligible patients could be treated at current and assumed net prices before crossing its budget impact threshold of $880 million annually. With a very large share of the U.S. adult population potentially eligible, that ceiling is reached almost immediately.
A new commentary in the Journal of Managed Care & Specialty Pharmacy makes the distinction explicit. "The ICER report shows that GLP-1s, at the cost that they are currently being sold, provide tremendous value to society," said Sujith Ramachandran, an associate professor of pharmacy administration at the University of Mississippi and a co-author, in remarks released with the analysis. He added that addressing obesity should in theory generate downstream savings in cardiovascular, liver and kidney conditions.
Cost-effective is not the same as cost-saving. A payer covering a policy year does not capture savings that arrive a decade later, particularly when members change plans. That gap, not a judgment about whether the drugs work, is what drives most denials.
Why Denials Cluster in Certain Plan Types
Coverage is not distributed randomly, and where you get your insurance largely predicts your answer.
ICER noted that as of 2025 only 13 state Medicaid programs and roughly one in five employer-based plans covered GLP-1 receptor agonists for obesity. Self-funded employer plans, in which the employer bears the claims cost directly, have been the most likely to exclude the category outright, because every prescription is a direct line item on the employer's budget rather than a pooled insurance risk.
Formulary decisions by pharmacy benefit managers add a second layer. NPR reported in April, citing a GoodRx analysis, that 12 million people lost coverage for Zepbound and 12 million lost coverage for Wegovy between 2025 and 2026, largely through formulary changes rather than individual denials. CVS Caremark spokesman Phillip Blando told NPR that the company's formulary strategy uses competition to drive down costs while maintaining clinically appropriate coverage, and said manufacturer list prices are the biggest barrier to access.
Indication matters too. A plan that excludes weight loss coverage may still cover the same molecule for a different approved use, such as tirzepatide for moderate to severe obstructive sleep apnea in adults with obesity, or semaglutide for cardiovascular risk reduction in adults with established cardiovascular disease. If you have one of those diagnoses documented, the coverage pathway is different.
What Exceptions and Appeals Actually Involve
Prescribers can supply specific documentation, and vague submissions are a common reason for denial.
Plans typically look for a documented body mass index with a recorded date, weight-related comorbidities with diagnosis codes, a record of prior weight management attempts including any lifestyle program, prior medications tried and why they failed or were not tolerated, and a clinical rationale for the specific agent requested. Where a plan imposes step therapy, a step therapy exception request should state why the preferred alternative is medically inappropriate rather than simply less desired.
For commercial coverage, the sequence is generally a corrected prior authorization or formulary exception request, then an internal appeal, then an external review by an independent third party. Deadlines are on the denial letter and are often short. For Medicare Part D, the sequence is a coverage determination, then a redetermination by the plan, then review by an independent review entity.
If coverage is genuinely unavailable, manufacturer direct-purchase channels and patient assistance programs run by Novo Nordisk and Eli Lilly are the next question to raise with a prescriber. ICER's own access white paper noted that direct cash pricing, while lower than list, still leaves the drugs out of reach for many people and does nothing to narrow existing disparities.
What Medicare's Temporary Program Does and Does Not Cover
Medicare beneficiaries have a distinct pathway that opened this month, with conditions worth understanding before counting on it.
The Medicare GLP-1 Bridge launched July 1, 2026, and runs through December 31, 2027, offering a flat $50 monthly copay for all formulations of Wegovy and Foundayo and the KwikPen formulation of Zepbound when prescribed to reduce excess body weight. Clinical criteria are assessed as of the time GLP-1 therapy was first initiated, not the date of the request.
The trade-offs are real. The Medicare Rights Center notes the program operates outside the Part D benefit, so the $50 copay does not count toward the deductible or the annual out-of-pocket limit, Extra Help cannot be applied, and no coupon can reduce it further. CMS has also clarified that a drug prescribed for a use already covered under Part D, such as Zepbound for obstructive sleep apnea, does not qualify under the Bridge and must go through the plan instead.
What Happens Next
The Bridge ends December 31, 2027, and the longer-term BALANCE model that was to follow has been postponed. Commercial formularies reset in January, and GoodRx has reported that CVS Caremark plans to return Zepbound to its standard formulary in October 2026, which would change the picture for some members.
Anyone with an active denial should work the deadline on the letter rather than waiting for market conditions to change. MedicalDaily will track formulary announcements, the fate of the BALANCE model, and any CMS guidance affecting Bridge eligibility.
Frequently Asked Questions
Why was I denied if the drug is considered cost-effective? Cost-effectiveness and affordability are different measures. ICER found the drugs deliver value at current prices but estimated that treating even 1 percent of eligible patients would exceed its $880 million annual budget impact threshold.
What is the first thing to do after a denial? Read the denial notice to identify whether it is a formulary exclusion, a prior authorization denial or a step therapy requirement, and note the appeal deadline. The remedy differs for each.
What documentation helps most? A dated BMI, comorbidity diagnosis codes, documented prior weight management attempts, prior medications tried with reasons for failure, and a clinical rationale for the specific drug requested.
Does having sleep apnea or heart disease change anything? Possibly. Some plans exclude weight loss but cover the same drug for other approved indications. Ask your prescriber whether a different documented indication applies to you.
Who is most likely to be denied? People in self-funded employer plans and in states whose Medicaid programs do not cover obesity treatment. Only 13 state Medicaid programs and about one in five employer plans covered these drugs for obesity as of 2025.
Can Medicare beneficiaries get the $50 copay? Eligible Part D enrollees can through the Medicare GLP-1 Bridge, but the copay does not count toward the deductible or out-of-pocket cap, and Extra Help does not apply.
What if I cannot afford it and cannot win an appeal? Ask your prescriber about manufacturer direct-purchase pricing and patient assistance programs. Do not substitute an unverified compounded or online source without clinical guidance.
